Clinical Outcomes of Neoadjuvant Chemoimmunotherapy vs. Chemoradiotherapy in Operable Non-Small Cell Lung Cancer

Authors

Tal Sherman, Thomas Jefferson University; Drexel UniversityFollow
Nikta Nair, Thomas Jefferson UniversityFollow
Marli Meller, Philadelphia College of Osteopathic Medicine,
Raleigh Anderson, Thomas Jefferson UniversityFollow
Guillermo Jimenez, Ponce Health Sciences University, Ponce, PR
Elizaveta Flevora, Thomas Jefferson University Hospital
Charalambos Solomides, Thomas Jefferson UniversityFollow
Rita Axelrod, Thomas Jefferson UniversityFollow
Sarah Gordon, Thomas Jefferson UniversityFollow
Ida Micaily, Thomas Jefferson UniversityFollow
Maria Werner-Wasik, Thomas Jefferson UniversityFollow
Sung Whang, Thomas Jefferson UniversityFollow
Tyler Grenda, Thomas Jefferson UniversityFollow
Olugbenga Okusanya, Thomas Jefferson UniversityFollow
Nathaniel R. Evans, III, Thomas Jefferson UniversityFollow
Nilanjan Haldar, Thomas Jefferson UniversityFollow
Erik Blomain, Thomas Jefferson UniversityFollow

Files

Description

Introduction

• Non-small cell lung cancer (NSCLC) accounts for ~85% of lung cancers and remains the leading cause of cancer death.
• Surgery is curative for early-stage disease, but recurrence rates remain high.
• CheckMate-816 trial established neoadjuvant chemo-immunotherapy (chemo-IO) as a new standard for resectable NSCLC, demonstrating improved pathologic response and event-free survival.
• PACIFIC trial showed the survival benefit of consolidative immunotherapy after chemoradiotherapy (chemo-RT) in unresectable stage III NSCLC, highlighting the synergy between radiation and immune checkpoint blockade.
• Despite these advances, there is little comparative data on the role of chemo-IO versus chemo-RT in the neoadjuvant, operable setting.
• Objective: To compare clinical outcomes between patients treated with neoadjuvant chemo-IO and those treated with chemo-RT prior to surgery at a single institution.

Publication Date

9-22-2025

Keywords

NSCLC, neoadjuvant, chemoimmunotherapy, chemoradiotherapy

Disciplines

Medicine and Health Sciences | Oncology | Radiation Medicine

Comments

Presented at the 2025 Department of Radiation Oncology Research Symposium.

Recommended Citation

Sherman, Tal; Nair, Nikta; Meller, Marli; Anderson, Raleigh; Jimenez, Guillermo; Flevora, Elizaveta; Solomides, Charalambos; Axelrod, Rita; Gordon, Sarah; Micaily, Ida; Werner-Wasik, Maria; Whang, Sung; Grenda, Tyler; Okusanya, Olugbenga; Evans, III, Nathaniel R.; Haldar, Nilanjan; and Blomain, Erik, "Clinical Outcomes of Neoadjuvant Chemoimmunotherapy vs. Chemoradiotherapy in Operable Non-Small Cell Lung Cancer" (2025). Department of Radiation Oncology Posters. 7.
https://jdc.jefferson.edu/radoncposters/7